SpringWorks Therapeutics filings document the company's completed acquisition by Merck KGaA, Darmstadt, Germany, and the resulting transition from a Nasdaq-listed public company to a wholly owned subsidiary. Material-event reports describe the merger closing, related merger-agreement disclosures, shareholder voting matters, capital-structure effects, and the status of SpringWorks common stock.
Subsequent exchange and SEC forms record the removal of SpringWorks common stock from Nasdaq listing and registration under Form 25 and the Form 15 notice terminating or suspending Exchange Act reporting obligations. Earlier filing categories include operating and financial results, governance matters, material agreements, and clinical or regulatory disclosures for its rare-disease and cancer therapy portfolio.